Medicine guide

Orserdu 86 mg

As listed in the register: Orserdu 86 mg, Filmtabletten

86 mg ·

  • Prescription only
  • Cancer treatments and immune-system medicines
Active substance
Elacestrantum
Made by
Stemline Therapeutics Switzerland GmbH

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Als Monotherapie zur Behandlung von postmenopausalen Frauen mit Estrogenrezeptor (ER) positivem, HER2-negativem, lokal fortgeschrittenem oder metastasiertem Brustkrebs mit einer aktivierenden ESR1-Mutation, deren Erkrankung nach mindestens einer endokrinen Therapielinie, kombiniert mit einem CDK 4/6-Inhibitor, fortgeschritten ist.

From the official label · 2026-09-30 · Swissmedic

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

SpainNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

Details

Made byStemline Therapeutics Switzerland GmbH
Active substanceElacestrantum
Used inCancer treatments and immune-system medicines
Strength86 mg
ClassificationL02BA04 · Cancer treatments and immune-system medicines
Dispensing (as stated by the register)Abgabekategorie B
Name in the registerOrserdu 86 mg, Filmtabletten
Packs28 Tablette(n)
Zulassungsnummer69417
Dosisstärke1

Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician

Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.